Trifecta Capital Advisors LLC Grows Position in GRAIL, Inc. $GRAL

Trifecta Capital Advisors LLC lifted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 89.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,650 shares of the company’s stock after purchasing an additional 10,250 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in GRAIL were worth $1,280,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in GRAIL by 768.1% during the second quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $42,000 after purchasing an additional 722 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after buying an additional 1,401 shares during the last quarter. Roble Belko & Company Inc purchased a new stake in shares of GRAIL during the 2nd quarter valued at $68,000. Cypress Capital Management LLC WY purchased a new stake in shares of GRAIL during the 2nd quarter valued at $72,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after acquiring an additional 623 shares during the last quarter.

GRAIL Price Performance

Shares of GRAIL stock opened at $100.98 on Friday. GRAIL, Inc. has a one year low of $20.44 and a one year high of $118.84. The business’s 50 day simple moving average is $98.12 and its two-hundred day simple moving average is $69.25. The stock has a market capitalization of $3.94 billion, a P/E ratio of -8.68 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $0.94. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. The firm had revenue of $36.19 million for the quarter, compared to analysts’ expectations of $33.83 million. Sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GRAL shares. Canaccord Genuity Group increased their target price on GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Guggenheim lifted their price target on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley increased their price objective on GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. UBS Group set a $75.00 price objective on GRAIL in a report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $105.00.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.